PCVX:NSD-Vaxcyte Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 66.4

Change

+0.44 (+0.67)%

Market Cap

USD 6.62B

Volume

0.51M

Analyst Target

USD 49.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-10.07 (-2.20%)

USD 117.92B
REGN Regeneron Pharmaceuticals Inc

-11.86 (-1.20%)

USD 108.54B
MRNA Moderna Inc

-13.41 (-8.05%)

USD 63.85B
ARGX argenx NV ADR

-0.73 (-0.20%)

USD 21.84B
BNTX BioNTech SE

-2.85 (-2.94%)

USD 21.84B
GMAB Genmab AS

+0.01 (+0.04%)

USD 19.15B
ALNY Alnylam Pharmaceuticals Inc

+2.30 (+1.56%)

USD 18.69B
BGNE BeiGene Ltd

+0.40 (+0.26%)

USD 17.32B
RPRX Royalty Pharma Plc

+0.02 (+0.08%)

USD 15.90B
BMRN Biomarin Pharmaceutical Inc

-1.09 (-1.44%)

USD 14.34B

ETFs Containing PCVX

SBIO ALPS Medical Breakthrough.. 5.12 % 0.50 %

N/A

USD 0.10B
HVAX:CA 4.86 % 0.00 %

N/A

N/A
GERM ETFMG Treatments Testing .. 3.52 % 0.00 %

-0.15 (0%)

USD 0.01B
BTEC Principal Healthcare Inno.. 1.62 % 0.42 %

-0.02 (0%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.73% 59% D- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.73% 59% D- 67% D+
Trailing 12 Months  
Capital Gain 30.48% 77% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.48% 77% C+ 78% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 27.55% 79% B- 84% B
Dividend Return 27.55% 79% B- 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.01% 53% F 32% F
Risk Adjusted Return 52.98% 94% A 82% B
Market Capitalization 6.62B 97% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector